Safety and Pharmacokinetics of LHF-535, a Potential Treatment for Lassa Fever, in Healthy Adults

LHF-535 is a small-molecule antiviral currently under development as a therapeutic option to treat Lassa fever and other viral hemorrhagic fevers of arenavirus origin. The human safety and pharmacokinetics of LHF-535 were evaluated in two phase 1 trials in healthy volunteers. The first study was a d...

Descripción completa

Detalles Bibliográficos
Autores principales: Amberg, Sean M., Snyder, Benjamin, Vliet-Gregg, Portia A., Tarcha, Eric J., Posakony, Jeff, Bedard, Kristin M., Heald, Alison E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664847/
https://www.ncbi.nlm.nih.gov/pubmed/36314868
http://dx.doi.org/10.1128/aac.00951-22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664847/
https://www.ncbi.nlm.nih.gov/pubmed/36314868
http://dx.doi.org/10.1128/aac.00951-22

Ejemplares similares